Baylor College of Medicine: Hodgkin Disease trials

The registry lists 21 Hodgkin Disease studies with Baylor College of Medicine as lead sponsor. 4 are open to participants now and 5 have results posted.

Phase 1 17Phase 2 2No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive LymphomasRecruitingNCT06176690Phase 1
• EBV Specific T-Lymphocytes for Treatment of EBV-Positive LymphomaRecruitingNCT04664179Phase 1
• CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)RecruitingNCT02917083Phase 1
• Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALERecruitingNCT01555892Phase 1
• Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)Active, not recruitingNCT02287311Phase 1Results posted
• Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's DiseaseCompletedNCT01702961Not applicableResults posted
• T-Regulatory Cell Kinetics, Stem Cell Transplantation, REGKINETerminatedNCT00578461Not applicableResults posted
• Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHDCompletedNCT00539695Phase 2Results posted
• LMP-specific T-cells for Patients With Relapsed EBV-positive LymphomaCompletedNCT00062868Phase 1Results posted
• (TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL).WithdrawnNCT05134740Phase 1
• Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive LymphomasWithdrawnNCT04952584Phase 1
• Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive LymphomasActive, not recruitingNCT04288726Phase 1
• Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)CompletedNCT02973113Phase 1
• Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12ACompletedNCT01858922Phase 2
• Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated DiseasesCompletedNCT01447056Phase 1
• Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTALCompletedNCT01333046Phase 1
• EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ LymphomaActive, not recruitingNCT01192464Phase 1
• Lmp1 and Lmp2 Specific CTLs Following Cd45 Antibody for Relapsed Ebv-Positive Hodgkin's Or Non-Hodgkin's LymphomaTerminatedNCT00383097Phase 1
• Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta)Active, not recruitingNCT00368082Phase 1
• Giving Gene Marked EBV Specific T-Cells to Patients Receiving a BMT for Relapsed EBV-Positive Hodgkin DiseaseTerminatedNCT00058773Phase 1
• Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells, Relapsed Lymphoma, ANGELCompletedNCT00058617Phase 1